Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Classical hematology 1

Conditions

Thrombocytopenia 1Recurrence 1Ovarian Neoplasms 1Neutropenia 1Fallopian Tube Neoplasms 1Anemia 1

Interventions

fludarabine phosphate 16Cyclophosphamide 16Antilymphocyte Serum 13Mycophenolic Acid 11Busulfan 11Radiotherapy 9Melphalan 9Cyclosporine 9Cord Blood Stem Cell Transplantation 9Peripheral Blood Stem Cell Transplantation 8Methylprednisolone 8Whole-Body Irradiation 6Tacrolimus 6Filgrastim 6Methotrexate 4fludarabine 3thymoglobulin 2Etoposide 2Cytarabine 2sargramostim 1niraparib 1merphos 1fanasil, pyrimethamine drug combination 1eltrombopag 1darinaparsin 1Transplantation 1Thiotepa 1Therapeutics 1Sirolimus 1Pharmacokinetics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × niraparib × Classical hematology × Clear all
NCT03891576 2025-01-17

Newton

Mario Negri Institute for Pharmacological Research

Phase 2 Terminated
83 enrolled
Classical hematologyGynecologic

Anemia, Fallopian Tube Neoplasms, Neutropenia, Ovarian Neoplasms, Recurrence, Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡